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Abstract Nuclear magnetic resonance (NMR)-based meta-
bolomics can be used directly to identify a variety of metabo-
lites in biological fluids and tissues. Metabolite analysis is an
important part of life science and metabolomics research.
However, the identification of some metabolites using NMR
spectroscopy remains a big challenge owing to low abundance
or signal overlap. It is important to develop a method to mea-
sure these compounds accurately. Two-dimensional NMR
spectroscopy, metabolite prediction software packages, and
spike-in experiments with authentic standards are often used
to solve these problems, but they are costly and time-consum-
ing. In this study, methods were developed to identify metab-
olites in complex biological mixtures using both high-
performance liquid chromatography (HPLC) and off-line mi-
croprobe NMR spectroscopy. With use of these methods, 83
and 73 metabolites were identified in Sprague Dawley rat
urine and feces, respectively. Among them, 40 and 45 metab-
olites, respectively, could not be identified with traditional
NMR methods. Our research revealed that the combination
of HPLC and NMR techniques could significantly improve
the accuracy of trace and overlappedmetabolite identification,
while offering an effective and convenient approach to iden-
tify potential biomarkers in complex biological systems.
Keywords High-performance liquid chromatography .
NMR . Urine . Feces .Metabolite identification
Introduction
Metabolomics is used to determine the metabolic profile
of biological samples, identify specific biomarkers, and
explore possible metabolic pathways. It has been used
during drug development [1], and in clinical disease re-
search [2, 3], pathology [4], toxicology [5] and nutrition
studies [6]. Metabolomics mainly utilizes NMR spectros-
copy [7], liquid chromatography (LC)–mass spectrometry
[8] and gas chromatography–mass spectrometry [9] to an-
alyze and evaluate biological specimens. Each analytical
technique has its own advantages and shortcomings; none
of them can be used individually to systematically and
accurately identify metabolites in complex biological ma-
trices. Since accurate metabolite identification directly de-
termines the usefulness of the metabolomic analysis, me-
tabolite identification has gained increased attention from
the metabolomics research community. 1H NMR spectros-
copy is often used for metabolomics research. As all 1H
nucleuses have the same sensitivity, the reproducibility of
NMR spectroscopy is typically high. In addition, speci-
mens do not go through complex processing, and can be
measured in the physiological state. Nevertheless, the lim-
ited spectroscopic dispersion of 1H NMR, about 12 ppm,
results in a high degree of overlap of metabolite signals.
Moreover, the signals of trace-level metabolites are often
too weak and unclear to be accurately assigned, even if
those signals do not overlap with other signals. Since
some metabolites with low concentrations are indicative
of certain disease states [10], it is important to measure
these metabolites with certainty.
In NMR-based metabolomics research, metabolite
identification is done mainly through the combined statis-
tical correlation between the experimental results and
those reported in the literature [11, 12], in databases
(Madison Metabolomics Consortium Database, Human
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Metabolome Database, etc.) [13, 14], by metabolite pre-
diction software packages (e.g., Chenomx NMR Suite)
[15, 16], and by related two-dimensional NMR spectros-
copy [17–21]. Two-dimensional NMR spectroscopy is ar-
guably the most important spectroscopic technique for the
elucidation of structures [22]; however, even if two-
dimensional NMR spectroscopy is used, assignments are
often challenging since signal overlap is extensive. The
method of multiple spike-in of authentic standards is also
used in metabolomics research [16]; however, standards
may be expensive and difficult to obtain.
High-performance LC (HPLC) can be used to reduce the
complexity of NMR spectra, and to increase the signal
strength of trace-level compounds. Preliminary HPLC en-
richment or purification, although time-consuming, is
sometimes necessary to establish the structural identities
of metabolites with low concentrations. For example, Liu
et al. [23] identified three polyphenolic compounds from a
well-researched plant, Origanum vulgare L, using LC–di-
ode-array detection–solid-phase extraction (SPE)–cryo-
NMR spectroscopy/mass spectrometry techniques. The
coupling of NMR spectroscopy and HPLC has been ap-
plied not only in the analysis of complex mixtures of nat-
ural products [24–26], but also in the study of biological
matrices. For example, Rezzi et al. [27] developed a new
method of combining HPLC with NMR spectroscopy, and
applied it to separate and identify 72 metabolites in human
urine, and to identify felinine in cat urine. Akira et al. [28]
used an LC–NMR approach to isolate and identify a pre-
viously unknown compound, succinyltaurine, in hyperten-
sive rat urine. Aranibar et al. [29] applied HPLC and NMR
spectroscopy to elucidate the previously unknown metab-
olites 1-methylhistidine and 3-methylhistidine as potential
biomarkers of drug-induced skeletal muscle toxicity and
hypertrophy in rats. In this study, microprobe NMR spec-
troscopy combined with HPLC was applied to improve
metabolite identifications in Sprague Dawley rat urine
and feces. The use of a microprobe provides a more con-
venient way to measure and quantify biological samples
with a limited volume/mass/cell count [30, 31]. Therefore,
our method could significantly shorten the time for sample
separation, enrichment, concentration, and collection, and
reduce the number of animals required.
In urine, most endogenous metabolites are polar small mol-
ecules, having poor retention on reversed-phase columns,
leading to co-elution of compounds corresponding to chro-
matographic peaks. Therefore, a hydrophilic interaction LC
(HILIC) column was used for separation of polar compounds
[32]. Sprague Dawley rats have been widely used for
NMR-based metabolomics research [33–35]. The choice
of their urine and feces as biological samples is justified




Sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4 (batch no.
1668-E) was purchased from Merck. Deuterium oxide
(D2O) was purchased from Cambridge Isotope Laboratories.
Methanol and acetonitrile (HPLC grade) were purchased from
Beijing Chemical Works. Water (HPLC grade) was purchased
from HangzhouWahaha Group. Dipotassium hydrogen phos-
phate (K2HPO4·3H2O), sodium dihydrogen phosphate
(NaH2PO4·2H2O), and hydrochloric acid (analytical grade)
were purchased from Beijing Chemical Works.
Instruments
The NMR instrument (AVANCE III-500), equipped with a
1.7-mm NMR microprobe, was from Bruker. The HPLC sys-
tem, equipped with a device for fraction collection (LC-20A),
was from Shimadzu. The high-speed centrifuge (Sartorius
Sigma 1-14) was purchased from Sigma. The freeze dryer
(FDU-1100) was from Tokyo Rikakikai. The nitrogen evapo-
rator (UGC-36M) was from Beijing Yousheng. The pHmeter
(MP511) was from Shanghai Sanxin. The analytical balance
(BT 124S) was from Sartorius.
Sample preparations
Male Sprague Dawley rats (each weighing about 200 g) were
purchased from Vital River Laboratory Animal Technology,
Beijing, China (license no. SCXK Beijing 2012-0001). All
protocols in this study were in accordance with regulations
for the care and use of animals in research implemented by
the National Institutes of Health. During the whole acclimati-
zation and study period, all rats had access to food and water
ad libitum, and were maintained on a 12 h light/dark cycle (21
±2 °C with a relative humidity of 45±10 %). After a 7-day
acclimatization period, rats were placed in metabolic cages,
and their urine and feces were collected for 24 h. Urine was
centrifuged at 12,000 revolutions per minute for 10 min to
remove solids, and the supernatant was collected. Urine su-
pernatant (1 mL) was stored at -20 °C for NMRmeasurement,
and the remaining material was freeze-dried to provide urine
powder for further analysis. Feces was stored at -20 °C for
further analysis.
K2HPO4·3H2O (3.4233 g) and NaH2PO4·2H2O (2.3402 g)
were dissolved in 10 mL D2O to prepare 1.5 M phosphate-
buffered saline. The pH was adjusted to 7.40, and 0.0500 g
sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4 was added as
an internal standard. The resulting solution was diluted tenfold
to provide 0.15 M phosphate-buffered saline.
Urine supernatant (180 μL) and 1.5 M phosphate-buffered
saline (20 μL) were transferred into a 0.6-mL microcentrifuge
3406 Z. Miao et al.
Table 1 1H NMR chemical shift assignment of metabolites in urine fractions

















e 2.16 (t), 1.53 (m), 1.29 (m)
3-Methylxanthinec CHe, CH3






f 7.53 (d), 6.94 (d), 7.45 (dd), 3.90 (s)
N-Methylhydantoinb NCH3
f, CH2




















f 3.54 (s), 7.30 (m), 7.38 (m), 7.31 (m)
Thyminec CH3
f, CHf 1.86 (d), 7.37 (q)
Uracilb NCHf, CCHf 7.55 (d), 5.80 (d)
Glycerolc CH3
f, CH3
f,CHf 3.56 (dd), 3.66 (dd), 3.79 (m)
Propionatec CH3
f, CH2






f 1.21, 1.22, 1.25, 1.26 (s, s, s, s), 5.22,




f 3.45 (s), 7.17 (m), 6.87 (m)
Creatininea CH3
f, CH2
f 3.04 (s), 4.05 (s)
Sarcosinec CH3
f, CH2
















f 4.49 (s), 9.29 (s), 8.91 (m), 8.19 (m), 8.97 (m)
3-Hydroxyisovalerateb CH3
f, CH2
f 1.27 (s), 2.37 (s)













f, CCHf, OCHf 3.74 (m), 4.03 (m), 4.53 (d)
Methylmalonatec CH3
f, CHf 1.24 (d), 3.17 (q)
Methylsuccinatec CH3
f, CH2





e 8.17 (s), 8.19 (s)
N-Acetylglycinec CH3
f, CH2











f 3.97 (s), 7.56 (m), 7.84 (m), 7.64 (m)
Lactateb CH3
f, CHf 1.33 (d), 4.12 (q)

















f 6.90 (d), 7.22 (d), 2.13 (s)
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tube and centrifuged at 12,000 revolutions per minute for
10 min. The supernatant (60 μL) was transferred into a 1.7-
mm NMR tube for NMR measurement. Urine powder (0.8 g)
was dissolved in 2 mL water of pH 3.0 (pH adjusted with
Table 1 (continued)





e 0.90, 0.94 (s, s), 3.40, 3.52 (d, d), 3.99 (s),
3.43 (m), 2.42 (t)
Taurineb NCH2
f, SCH2




f 2.04 (s), 4.15 (m), 2.33 (m), 1.93, 2.12 (m, m)
Pyroglutamatec C2H2
f, C3H2
e, CHf 2.04, 2.51 (m, m), 2.41 (m), 4.18 (dd)
Betaineb CH3
f, CH2
f 3.27 (s), 3.91 (s)
2-Oxoglutaratea C3H2
f, C4H2












f 4.44 (s), 9.13 (s), 8.84 (m), 8.09 (m), 8.84 (m)
N,N-Dimethylglycineb CH3
f, CH2













f, CHf 3.13 (d), 5.73 (t)
Glutaratec C2,4H2
f, C3H2
f 2.19 (m), 1.79 (m)
Valinec CH3
f 1.00, 1.05 (d, d)
Malatec CH2










f 3.59 (dd), 1.67, 2.20 (m, m), 1.58, 1.89 (m, m),





f 4.14 (dd), 2.06, 2.35 (m, m), 1.98, 2.02 (m, m),
3.35, 3.42(m, m)
Tartrateb CHe 4.34 (s)
trans-Aconitatec CH2
f, CHf 3.45 (d) , 6.59 (t)
Alanineb CH3
f, CHf 1.49 (d), 3.79 (q)
Creatineb CH3
f, CH2
f 3.04 (s), 3.93 (s)
5,6-Dihydrouracilc C5H2
e, C6H2














e 2.29 (t), 1.89 (m), 3.01 (t)
Ethanolaminec C1H2
f, C2H2
e 3.14 (d), 3.82 (d)
Citratea CH2
f, CH2











f 4.07 (t), 4.24 (d), 3.68, 3.69 (s, s), 5.44 (d),
3.58 (dd), 3.54 (t)
TMAO trimethylamine N-oxide, s singlet, d doublet, t triplet, q quartet, dd doublet of doublets, m multiplet
a Already clearly identified in the reference urine profile
b Clearer in fractions than in the reference urine profile
c Could not be seen in the reference urine profile
d Still not clear in fractions
e Putative assignment
f Positive assignment
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Table 2 1H NMR chemical shift assignment of metabolites in feces fractions
Metabolite Assignment δ 1H (ppm) and multiplicity
Ethanola CH3
d, CH2
d 1.19 (t), 3.66 (q)
Glycerola CH3
d, CH3
d, CHd 3.56 (dd), 3.65 (dd), 3.79 (m)
Lactatea CH3
d, CHd 1.33 (d), 4.12 (q)




d 4.03 (dd), 1.85, 2.00 (m, m), 2.26 (m)
Aspartateb C2H
d, C3H2




d 3.77 (dd), 2.10 (m), 2.35 (m)
Glutarateb C2,4H2
d, C3H2





















d 4.66, 5.24 (d, d), 3.26, 3.55 (dd, dd), 3.50, 3.72 (t,t),











e 3.90 (dd), 3.66 (dd), 3.75 (m), 3.79 (d)
Propionatec CH3
d, CH2








d 0.84, 0.97 (d, d), 3.85 (d), 2.01 (m)
4-Hydroxybenzoateb C2,6H
d, C3,5H












e 2.16 (t), 1.56 (m), 1.29 (m)
Fucoseb CH3
d, C1H












d 8.95 (m), 8.26 (m), 7.53 (m), 8.60 (m)
Urocanateb C2H
d, C5H



























d 3.45 (s), 7.17 (m), 6.87 (m)
Creatininea CH3
d, CH2













d 3.74 (d), 2.07 (m), 1.35, 1.45 (m, m), 0.95 (d), 0.97 (t)
Isovalerateb CH2
d, CHe, CH3































d 3.48 (s), 6.81 (m), 6.80 (m), 7.26 (t), 6.86 (m)
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hydrochloric acid) and centrifuged at 12,000 revolutions per
minute for 10 min. The supernatant was filtered through a
0.45-μmmembrane filter before it was used for HPLC analysis.
Feces (0.4 g) and 0.15M phosphate-buffered saline (1 mL)
were placed in a mortar and ground to a suspension. The
suspension was transferred into a 1.5-mL microcentrifuge
tube and centrifuged at 12,000 revolutions per minute for
10 min. The supernatant (60 μL) was transferred into a 1.7-
mm NMR tube for NMR measurement. Feces (4 g) and water
(10 mL) were placed in a mortar and ground to a suspension.
The mixture was transferred into 1.5-mL microcentrifuge
tubes, and centrifuged at 12,000 revolutions per minute for
10 min. The supernatant (2 mL) was filtered through a
0.45-μm membrane filter before HPLC analysis.
HPLC analysis methods
The preconcentrated urine (as described in the previous section,
100 μL) was analyzed using a HILIC analytical column
(Shimadzu, 5 μm, 4.6 mm×250-mm inner diameter) equipped
with a HILIC cartridge guard column (Shimadzu, 5 μm,
4.6 mm×10-mm inner diameter). Separation was achieved in
Table 2 (continued)
Metabolite Assignment δ 1H (ppm) and multiplicity
1,3-Dihydroxyacetoneb CH2
e, CH2
e 3.57 (s),4.41 (s)
2-Hydroxybutyrateb CHe, CH2
e, CH3
















d, αCHd, βCHd 7.20 (m), 6.91 (m), 3.95 (dd), 3.07, 3.20 (dd, dd)
Isobutyrateb CH3






























e 2.04 (s), 4.17 (m), 1.75, 1.84 (m, m), 1.69 (m), 3.01 (m)
Isovalerateb CH3
e, CH2






d 5.91 (d), 7.88 (d), 5.93 (d), 4.36 (t), 4.24 (t)
Thymineb CH3



















d 6.50 (t), 2.56, 2.85 (m, m), 4.66 (m), 4.18 (m),












e 8.24 (s), 7.12 (s), 4.44 (m), 3.04, 3.20 (dd, dd),








e 1.90 (d), 7.65 (m), 6.31 (t), 2.38 (dd), 4.48 (m),







d,αCHd 7.34 (s), 7.74 (m), 7.20 (m), 7.29 (m), 7.55 (m),





d 7.23 (m), 6.92 (m), 2.93(t), 3.24 (t)
s singlet, d doublet, t triplet, q quartet, dd doublet of doublets, m multiplet
a Clearer in fractions than in the reference urine profile
b Could not be seen in the reference urine profile
c Already clear in the reference urine profile
d Positive assignment
e Putative assignment
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50 min at 40 °C with a flow rate of 1 mL/min. The mobile
phase consisted of water (solvent A) and acetonitrile (solvent
B) and the elution gradient was 95 % solvent B for 20 min
followed by 95 % solvent B to 65 % solvent B in 30 min.
Fractions were collected at 1-min intervals, for a total of ten
injections. The fractions were each evaporated under a stream
of nitrogen to remove acetonitrile. The remaining aqueous res-
idue from each fraction was lyophilized in a freeze dryer.
The aqueous feces extract (100 μL) was analyzed using
HPLC with a C18 analytical column (5 μm, 4.6 mm×250-
mm inner diameter) equipped with a C18 cartridge guard col-
umn (5 μm, 4.6 mm×10-mm inner diameter ), both purchased
from Shanghai Puning Analytical Technology. Separation was
achieved in 30 min at 30 °C with a flow rate of 1 mL/min. The
mobile phase consisted of water (solvent A) and methanol (sol-
vent B) with a gradient elution of 0 % solvent B for 10 min
followed by 0 % solvent B to 90 % solvent B in 20 min.
Fractions were collected at 1-min interval, for a total of ten
injections. The fractions were each evaporated under a stream
of nitrogen to remove methanol. The remaining aqueous resi-
due from each fraction was lyophilized in a freeze dryer.
NMR analysis
Each freeze-dried urine and feces fraction was dissolved in
70 μL 0.15 M phosphate-buffered saline and transferred into
a 1.7-mm NMR tube for NMR measurement.
Nuclear Overhauser effect spectroscopy (NOESY) pulse
sequence (recycle delay–90°–t1–90°–tm–90°–acquisition),
1H–13C heteronuclear single quantum correlation (HSQC)
spectroscopy, and 1H–1H homonuclear total correlation spec-
troscopy (TOCSY) spectra were collected for each fraction at
Fig. 1 Typical 1H nuclear Overhauser effect spectroscopy (NOESY)
spectra of rat urine. 1 3-hydroxyisovalerate, 2 lactate; 3 2-
hydroxyisobutyrate, 4 alanine, 5 acetate, 6 acetamide, 7 acetone, 8 pyru-
vate, 9 2-oxoglutarate, 10 methylamine, 11 succinate, 12 citrate, 13
dimethylamine, 14 methylguanidine, 15 trimethylamine, 16 N,N-
dimethylglycine, 17 N-methylhydantoin, 18 creatine, 19 creatinine, 20
cis-aconitate, 21 malonate, 22 choline, 23 betaine, 24 trimethylamine N-
oxide, 25 taurine, 26 glycine, 27 ethylene glycol, 28 N-
phenylacetylglycine, 29 guanidoacetate, 30 glycolate, 31 tartrate, 32
trigonelline, 33 1-methylnicotinamide, 34 allantoin, 35 uracil, 36 urea,
37 fumarate, 38 4-hydroxyphenylacetate, 39 3-indoxylsulfate, 40
hippurate, 41 benzoate, 42 xanthine, 43 hypoxanthine, 44 formate
Fig. 2 Typical 1H NOESY
spectra of water-extracted rat fe-
ces. 1 butyrate, 2 leucine, 3 va-
line, 4 propionate, 5 ethanol, 6
lactate, 7 alanine, 8 acetate, 9
acetamide, 10 methionine, 11
glutamate, 12 pyruvate, 13 succi-





20 malonate, 21 choline, 22 pro-
line, 23 glucose, 24 glycine, 25
glycerol, 26 glycolate, 27 benzo-
ate, 28 formate
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25 °C. For the NOESY pulse sequence, a total of 128 tran-
sients were collected into 81,920 data points for each spectrum
with a spectroscopic width of 16 ppm and a recycle delay of
4.0 s. The mixing time (tm) was 100 ms, and the acquisition
time was 5.12 s. For HSQC spectroscopy, 128 increments
with 256 transients per increment were collected into 1,024
data points with a spectroscopic width of 5,000 and 26,000 in
the first and second dimensions, respectively. The coupling
constant (J) was set at 145 Hz. The TOCSY NMR spectra
were acquired with 128 transients per increment, with 256
increments collected into 2,048 data points, using the MLEV
PHPP pulse program with a mixing time of 80 ms. A line-
broadening factor of 0.3–1.0 Hz was applied to the free induc-
tion decay before Fourier transformation.
Results
The resonances were assigned to specific metabolites accord-
ing to assignments reported in the literature, including the
500-MHz library from Chenomx NMR Suite 7.5 (Chenomx,
Edmonton, AB, Canada) and the Human Metabolome Data-
base. NMR analysis of the HPLC (HILIC and C18) fractions
identified 83 and 73 metabolites in rat urine and feces,
Fig. 3 Comparison of urine
metabolite identifications from 1H
NMR spectra of high-
performance liquid chromatogra-
phy (HPLC) fractions (upper
spectra) and from the reference
profile (lower spectra)
Fig. 4 Comparison of feces
metabolite identifications from 1H
NMR spectra of HPLC fractions
(upper spectra) and from the
reference profile (lower spectra)
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respectively (Tables 1, 2, Figs. S1–S8), whereas 40 and 45
metabolites, respectively, could not be identified in the NMR
spectra of non fractionated urine and feces samples (called
Bthe reference urine profile^ and Bthe reference feces profile,
^ respectively; Figs. 1, 2).
With the HPLC enrichment methods, metabolites could be
clearly recognized, as shown in Figs. 3a and 4a. Moreover, some
trace amounts ofmetabolites could be clearly observed, as shown
in Figs. 3b and 4b. In each figure, the upper spectra are the
measurement results of the HPLC fractions, and the lower spec-
tra show the same chemical shift range from 1H NOESY NMR
spectra of reference urine and feces samples. Here 3-indoxyl
sulfate and valine are used as examples to explain how our meth-
odworked. In Fig. 3a, 3-indoxyl sulfate shows strong resonances
without interfering signals from other metabolites in the urine
fraction. But it could not be clearly identified in the reference
urine profile, owing to the overlapped resonances. The result for
valine was the same as shown in Fig. 4a. Valine had apparent
characteristic peaks in the HPLC fraction, but the signals were
veryweak in the reference feces profile because 3-H could not be
clearly identified. Phenylacetate and 2-hydroxyglutarate are used
as examples to explain how trace amounts of metabolites could
also be clearly identified using this method. In Fig. 3b,
phenylacetate has very clear resonances in the HPLC urine frac-
tions, but shows no signal in the reference urine profile. Figure 4b
shows that 2-hydroxyglutarate had obvious characteristic
signals in the HPLC feces fractions, but not in the ref-
erence feces profile.
In complex biological systems,there are many similar struc-
tures or groups of metabolites, called homologues or deriva-
tives, such as the seven metabolites shown in Fig. 5. Their
signals are very dense between 2.0 and 4.0 ppm in 1H NMR
spectra. Owing to changes of chemical shifts under different
environments, it is difficult to identify the corresponding peaks
in the reference spectrum (Fig. 5, spectrum A). HPLC provides
a better characterization method (Fig. 5, spectrum B). Among
the fractions, 2-hydroxyglutarate (Fig. 5, spectrumC), aspartate
(Fig. 5, spectrum D), glutarate (Fig. 5, spectrum E), and lysine
(Fig. 5, spectrum F) could be recognized, whereas glutamate
(Fig. 5, spectrum G) was better recognized in the fraction than
in the reference feces profile. Further experiments were per-
formed using the combined techniques of HPLC and two-
dimensional HSQC or TOCSY NMR spectroscopy to verify
metabolite identities. All 1H–13C single bond signals and
1H–1H totally correlated signals are shown clearly in Fig. 6.
Both glycine (Fig. 5, spectrum H) and succinate (Fig. 5, spec-
trum I) had one single resonance in the 1H NMR spectrum, and
in Fig. 6, spectrum A, their 1H–13C single-bond correlated sig-
nals are further identified (Table 3).
Discussion
Jacobs et al. [36] previously applied SPE–NMR-based meta-
bolomics during nutritional intervention trials. Their study
proved that SPE–NMR-based metabolite subprofiling was a
Fig. 5 Typical comparison
between the reference sample,
fraction 3, and standard
substances (from Chenomx NMR
Suite 7.7 Library Manager). A
reference sample, B fraction 3, C
2-hydroxyglutarate, D aspartate,
E glutarate, F lysine,G glutamate,
H glycine, I succinate
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reliable and improved method, compared with the NMR ap-
proach, for metabolite identification in urine. In their experi-
ments, an SPE column was used to separate each urine sample
into three fractions to achieve more accurate metabolite quan-
tification and identification, especially for the metabolites with
low concentrations. In our experiment, HILIC and C18 analyt-
ical columns were applied to obtain improved metabolite
subprofiling. The 1.7-mm microprobe can reduce the sample
volume to one tenth of that for an ordinary probe, and contacted
well with samples we collected from the liquid-phase analysis.
Therefore, our method could significantly shorten the time for
sample separation, enrichment, concentration, and collection,
and reduce the number of animals required. In this research,
we needed only 10 h to complete the sample separation and
enrichment. In addition, it took only a fewminutes to collect 1H
NMR spectra for each collected sample fraction and a few
hours to collect two-dimensional spectra for that fraction.
To ensure that fractions and the original sample were mea-
sured under the same neutral or weak alkaline condition, so
that the chemical shifts of the two spectra are comparable,
after freeze-drying, the separated fractions were dissolved in
a buffer which had the same saline ratio as the buffer for the
control. NMR experiments showed that the chemical shifts of
metabolites in both spectra were similar (Fig. 5, spectra A and
B), suggesting that the results were valid.
Among the 83 metabolites identified from rat urine, 20 had
very simple NMR spectra with only a single resonance, such
as an acetate or dimethylamine peak. To improve identifica-
tion of those 20 metabolites, the interfering peaks from other
metabolites must be removed. Therefore, it was necessary to
Fig. 6 Typical heteronuclear single quantum correlation (A) and total
correlation spectroscopy (B) spectra of the feces HPLC (C18) fraction.
For spectrum A, 1, 2 2-hydroxyglutarate (3-CH2), 3 2-hydroxyglutarate
(4-CH2), 4 2-hydroxyglutarate (2-CH), 5, 6 aspartate (3-CH2), 7 aspartate
(2-CH), 8 glutamate (3-CH2), 9 glutamate (4-CH2), 10 glutamate (2-CH),
11 glutarate (3-CH2), 12 glutarate (2,4-CH2), 13 glycine (2-CH2), 14
lysine (4-CH2), 15 lysine (5-CH2), 16 lysine (3-CH2), 17 lysine (6-
CH2), 18 lysine (2-CH), 19 succinate (2,3-CH2). For spectrum B, 1, 4
2-hydroxyglutarate (3H–3H), 2, 5 2-hydroxyglutarate (3H–4H), 3, 6 2-
hydroxyglutarate (3H–2H), 7, 8 2-hydroxyglutarate (4H–3H), 9 2-
hydroxyglutarate (4H–2H), 10, 11 2-hydroxyglutarate (2H–3H), 12 2-
hydroxyglutarate (2H–4H), 13, 15 aspartate (3H–3H), 14, 16 aspartate
(3H–2H), 17, 18 aspartate (2H–3H), 19 glutamate (3H–4H), 20 glutamate
(3H–2H), 21 glutamate (4H–3H), 22 glutamate (4H–2H), 23 glutamate
(2H–3H), 24 glutamate (2H–4H), 25 glutarate (3H–2,4H), 26 glutarate
(2,4H–3H), 27 lysine (4H–5H), 28 lysine (4H–3H), 29 lysine (4H–6H),
30 lysine (4H–2H), 31 lysine (5H–4H), 32 lysine (5H–3H), 33 lysine
(5H–6H), 34 lysine (5H–2H), 35 lysine (3H–4H), 36 lysine (3H–5H),
37 lysine (3H–6H), 38 lysine (3H–2H), 39 lysine (6H–4H), 40 lysine
(6H–5H), 41 lysine (6H–3H), 42 lysine (6H–2H), 43 lysine (2H–4H),
44 lysine (2H–5H), 45 lysine (2H–3H), 46 lysine (2H–6H)
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separate those metabolites using analytical columns. Some
metabolites might have overlapping resonances or have con-
centrations below the NMR detection limit in the reference
urine sample. With the separation and enrichment using the
HPLCmethod, those metabolites were identified in the HPLC
fractions. Among the 40 metabolites only identified in frac-
tions, 25 were positively identified, because of their complex
characteristic or their strong resonances. The other 15 metab-
olites were putatively identified, such as N-acetylglycine, 1,3-
dimethylurate, and proline. N-Acetylglycine had a simple
spectrum with a single resonance and a doublet at about
2.03 and 3.74 ppm. It was putatively recognized, because
the resonance at 2.03 ppm was clear but the 3.74-ppm reso-
nance was obscured. 1,3-Dimethylurate had only two single
resonances at 3.44 and 3.31 ppm. Since the two resonances
were weak and close to other resonances, 1,3-dimethylurate
could only be putatively identified. Proline had six groups of
multiple resonances and one doublet of doublets. Among
them, only the doublet of doublets at 4.14 ppm and one mul-
tiplet at 3.35 ppm could be positively identified. The other five
multiplets were covered by other resonances. Proline could
therefore only be putatively identified.
Among the 45 metabolites discovered in only feces frac-
tions, 29 were positively identified, and the remaining 16 were
putatively identified. All resonances of the 29 positively iden-
tified metabolites were clear and obvious, except for those of
lysine, 2-hydroxy-3-methylvalerate, 3-phenylpropionate, and
thymidine. Those four compounds all had complex spectra;
however, most of their characteristic resonances were clear.
Therefore, they were classified as positively identified. Fucose
had four singlets at 1.21, 1.22, 1.25, and 1.26 ppm, two dou-
blets, at 5.21 and 4.56 ppm, and several between 3.40 and
4.20 ppm. However, only four single peaks and two double
peaks were positively identified. The other peaks were covered
by other resonances. Fucose was therefore only putatively iden-
tified. And it was the same for the other 15 compounds.
Compound identification is an important and difficult task
in metabolomics research. The accuracy of metabolite identi-
fication directly affects the results of metabolomic biological
analysis. Some metabolites are important biomarkers for cer-
tain diseases, but they are often ignored owing to their low
concentration and difficulty of identification. Urine and feces
have been widely used as samples in many metabolomic stud-
ies, because of their relative ease of collection and low protein
contents. Here, phenylacetate and 2-hydroxyglutarate are used
as examples to elucidate how our methods worked. Both
chemicals are present at very low concentrations in urine,
and could be identified only through a fractional enrichment
method. Plasma phenylacetate has been analyzed in patients
with urination disorders or hepatic encephalopathy [37]. How-
ever, it has not been identified and quantified in urine or feces
profiles. With use of our methods, urine and feces
phenylacetate could be measured for the analysis of these
diseases. The metabolic profiles of feces, plasma, and tu-
mor tissue could be very useful in colorectal cancer diag-
nosis and treatment [38]. High levels of 2-hydroxyglutarate
have been reported in both tumor tissues and plasma, but
have not been found in urine and feces because of the
Table 3 The NMR signal
assignment of metabolites in a
feces fraction
HSQC heteronuclear single
quantum correlation, TOSCY total
correlation spectroscopy
Metabolite δ 1H (ppm) HSQC δ 1H–13C (ppm) TOCSY δ 1H–1H (ppm)
2-Hydroxyglutarate 1.85 1.85, 33.55 1.86, 2.00; 1.86, 2.27; 1.85, 4.03
2.00 1.99, 33.55 2.01, 1.85; 2.00, 2.26; 1.99, 4.03
2.26 2.25, 36.35 2.27, 1.85; 2.25, 2.01; 2.26, 4.03
4.03 4.03, 74.94 4.03, 1.86; 4.03, 2.01; 4.03, 2.26
Aspartate 2.69 2.71, 39.35 2.69, 2.81; 2.69, 3.91
2.81 2.80, 39.34 2.82, 2.69; 2.80, 3.91
3.90 3.91, 54.99 3.91, 2.70; 3.91, 2.81
Glutamate 2.10 2.11, 29.79 2.10, 2.36; 2.10, 3.78
2.35 2.35, 36.22 2.35, 2.10; 2.35, 3.78
3.77 3.77, 57.35 3.77, 2.10; 3.78, 2.36
Glutarate 1.79 1.78, 25.77 1.80, 2.20
2.19 2.18, 40.08 2.20, 1.80
Glycine 3.57 3.57, 44.32 No signal
Lysine 1.48 1.48, 24.50 1.48, 1.74; 1.48, 1.92; 1.48, 3.03; 1.48, 3.77
1.74 1.74, 29.11 1.74, 1.48; 1.74, 1.92; 1.74, 3.03; 1.74, 3.77
1.92 1.92, 32.70 1.92, 1.48; 1.92, 1.74; 1.92, 3.03; 1.92, 3.77
3.03 3.03, 41.82 3.03, 1.48; 3.03, 1.74; 3.03, 1.92; 3.03, 3.77
3.77 3.77, 57.35 3.77, 1.48; 3.77, 1.74; 3.77, 1.92; 3.77, 3.03
Succinate 2.41 2.40, 36.97 No signal
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limitation of the previous analytical methods. In our re-
search, 2-hydroxyglutarate could be clearly identified in
rat urine and feces. Therefore, with our method, colorectal
cancer could be diagnosed much more conveniently using
urine and feces samples.
Conclusion
For NMR-based metabolomics research, the identification of
some metabolites remains a big challenge owing to low abun-
dance or strong signal overlaps. In this study, NMR spectros-
copy combined with HPLC was applied to identify metabo-
lites in complex biological mixtures. With this method, 83 and
73 metabolites were identified in Sprague Dawley rat urine
and feces, respectively. We believe that more metabolites
could be accurately identified by changing the chromato-
graphic development conditions, using different columns, or
changing the fraction collection time. Our research revealed
that the coupling of HPLC and microprobe NMR spectrosco-
py techniques could improve metabolite identification, and is
an effective and convenient approach to recognize biomarkers
in complex biological systems.
At the same time, we also noticed that there were many
visible peaks in the fragment spectra, but their structures could
not be confirmed. Further work will be performed using the
coupled HPLC, NMR spectroscopy, and mass spectrometry
analysis method to characterize the structures from those peaks.
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